Skip to main content

Table 1 Baseline characteristics

From: Galcanezumab in episodic migraine: subgroup analyses of efficacy by high versus low frequency of migraine headaches in phase 3 studies (EVOLVE-1 & EVOLVE-2)

 

LFEM Mean (SD)

HFEM Mean (SD)

LFEM vs HFEM p-value *

Number of patients (%)

597 (33.7)

1176 (66.3)

 

Age at randomization, years

42 (11.4)

41 (11.4)

.069

MHDs

5.79 (1.11)

10.82 (2.01)

<.001

MHDs with acute medication use

4.82 (1.73)

8.81 (3.27)

<.001

MHDs with nausea and vomiting

2.20 (1.98)

4.66 (3.36)

<.001

MHDs with photophobia and phonophobia

4.08 (2.17)

8.26 (3.52)

<.001

MHDs with aura

1.40 (2.03)

3.04 (3.65)

<.001

MHDs with prodrome

1.89 (2.11)

3.86 (3.77)

<.001

MSQ-RFR score

55.8 (15.8)

49.5 (15.4)

<.001

MIDAS total score

26.3 (22.9)

36.6 (30.7)

<.001

  1. * P-value from Analysis of Variance model with terms for study, baseline MHD frequency subgroup
  2. HFEM: high-frequency episodic migraine; ITT: intent-to-treat; LFEM: low-frequency episodic migraine; MHDs: migraine headache days; MIDAS: Migraine Disability Assessment; MSQ-RFR v2.1: Migraine-Specific Quality of Life Questionnaire v2.1 Role Function-Restrictive